Strategic Partnering Opportunities

Echo owns all rights to its new Symphony™ tCGM System. Symphony represents a valuable, late-stage, multiple-market partnering opportunity for companies interested in building or expanding their presence in the diabetes home use market care and those focused on late-stage product opportunities for the hospital critical care market.

For companies looking for a product-life-cycle extension or a new, proprietary transdermal reformulation platform, Echo is the strategic partner of choice. Echo's AzoneTS™ transdermal reformulation platform, patented through 2019, offers reforumlation opportunities for products previously approved by the FDA.  AzoneTS is a valuable life-cycle management asset for line-extensions of existing products and a renewable source of advanced formulations of FDA-approved drugs. Echo expects most of its AzoneTS pipeline programs to be amenable to the FDA's Section 505(b)(2) guidelines.   

Edit Page Add Page